🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Refractory Solid Tumor

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor NCT06615193Phase 18 sites📍 Zhengzhou📍 Suzhou📍 Suzhou Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDM2005 IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites📍 Heidelberg📍 Heidelberg📍 Mannheim Immatics Biotechnologies GmbH · Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors NCT06730659Phase 11 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT101 GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases NCT07697937Phase 21 site📍 Tianjin Tianjin First Central Hospital · Tests: YH-02 A Study of PHST001 in Advanced Solid Tumors NCT06840886Phase 120 sites📍 Beverly Hills📍 Los Angeles📍 Palo Alto Pheast Therapeutics · Tests: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site📍 Wuxi Wuxi People's Hospital · Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272Phase 1, Phase 264 sites📍 Los Angeles📍 Aurora📍 New Haven Merck Sharp & Dohme LLC · Tests: Patritumab Deruxtecan ML-016 in Advanced Cancer With Lung and/or Liver Involvement NCT07723482Phase 1, Phase 23 sites📍 Miranda📍 Wollongong📍 Buderim BrYet US, Inc. · Tests: ML-016 APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors NCT05701306Phase 1, Phase 23 sites📍 Guangzhou📍 Wuhan📍 Tianjin Ascentage Pharma Group Inc. · Tests: APG-115, APG-2575 CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors NCT07800936Phase 11 site📍 Changchun Parr Biotechnology (Hebei) Co., Ltd. · Tests: HP007 KSH01-TCRT Solid Tumors NCT05539833EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSH01 injection Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors NCT06940349Phase 1, Phase 21 site📍 Petah Tikva Rabin Medical Center · Tests: Palbociclib, Sunitinib GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours NCT07297667Phase 14 sites📍 Calgary📍 Ottawa📍 Toronto Canadian Cancer Trials Group · Tests: Fludarabine, Cyclophosphamide, GCAR1 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors NCT06063681Phase 13 sites📍 Randwick📍 Clayton📍 Frankston Stingray Therapeutics · Tests: SR-8541A, Immune checkpoint inhibitor (ICI) IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib KSX01-TCRT Injection Project in Solid Tumors NCT05811975EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSX01-TCRT injection RAPA-201 Therapy of Solid Tumors NCT05144698Phase 1, Phase 21 site📍 Hackensack Rapa Therapeutics LLC · Tests: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors NCT06014502Phase 113 sites📍 Gilbert📍 Orange📍 Santa Monica ImmunoGenesis · Tests: IMGS-001
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy